Abstract
The repeated failure of clinical trials targeting the amyloid beta (Aβ) protein has challenged the amyloid cascade hypothesis. In this perspective, I discuss the biogenesis and biology of Aβ, from the arrangement of its atoms to its effects on the human brain. I hope that this analysis will help guide future attempts to home in on this elusive therapeutic target.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1561-1567 |
| Number of pages | 7 |
| Journal | Alzheimer's and Dementia |
| Volume | 16 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2020 |
Bibliographical note
Funding Information:I thank David Knopman and Rob Tycko for provocative discussions and insightful comments about this manuscript, and Peng Liu for his vital contributions to the delineation and characterization of type 1 and type 2 oligomers in the brain. Funding: NIH R01-NS/AG33249, B. Grossman, T. and P. Grossman Family Foundation.
Publisher Copyright:
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association